Biology of Blood and Marrow Transplantation
Volume 12, Issue 1 , Pages 68-74 , January 2006

Tumor Cell Purging by Ex Vivo Expansion of Hemopoietic Stem Cells from Breast Cancer Patients Combined with Targeting ErbB Receptors

Received 30 March 2005 ,Accepted 25 June 2005.

References 

  1. Nieto Y . The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer . Haematologica . 2003;88:201–211
  2. Nieto Y , Jones RB , Shpall EJ . High-dose chemotherapy for breast cancer (is another look warranted?) . Curr Opin Oncol . 2004;16:114–119
  3. Solano C , Badia B , Lluch A , et al.   Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation . Bone Marrow Transplant . 2001;27:287–293
  4. Syme R , Stewart D , Rodriguez-Galvez M , et al.   Micrometastases in apheresis products predicts shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT) . Bone Marrow Transplant . 2003;32:307–311
  5. Patriarca F , Sacco C , Sperotto A , et al.   Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy . Bone Marrow Transplant . 2003;31:789–794
  6. Reed E , Kessinger A , Murphy B , Tarantolo S , Traystman M , Sharp JG . Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation . Bone Marrow Transplant . 2003;31:571–574
  7. Viret F , Chabannon C , Sainty D , et al.   Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy . Bone Marrow Transplant . 2003;32:1059–1064
  8. Pecora AL , Lazarus HM , Jennis AA , et al.   Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer (predictors and clinical relevance) . Biol Blood Marrow Transplant . 2002;8:536–543
  9. Nieto Y , Franklin WA , Jones RB , et al.   Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support . Biol Blood Marrow Transplant . 2004;10:415–425
  10. Ferrucci PF , Rabascio C , Mazzetta C , et al.   Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer . Clin Cancer Res . 2004;10:6039–6046
  11. Brenner MK , Rill DR , Moen RC , et al.   Gene marking to trace origin relapse after autologous bone marrow transplantation . Lancet . 1993;341:85–86
  12. Deisseroth AB , Zu Z , Claxton D , et al.   Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation for CML . Blood . 1994;3:3068–3076
  13. Kasimir-Bauer S , Mayer S , Bojko P , Borquez D , Neumann R , Seeber S . Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy . Clin Cancer Res . 2001;7:1582–1589
  14. Rill DR , Santana VM , Roberts WM , et al.   Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells . Blood . 1994;84:380–383
  15. Ross AA , Cooper BW , Lazarus HM , et al.   Detection and viability of tumor cells in peripheral blood stem cell collection from breast cancer patients using immunocytochemical and clonogenic assay techniques . Blood . 1993;82:2605–2610
  16. Passos-Coelho JL , Ross AA , Kahn DJ , et al.   Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor . J Clin Oncol . 1996;9:2569–2575
  17. Lundell BI , Vredenburgh JJ , Tyer C , DeSombre K , Smith AK . Ex vivo expansion of bone marrow from breast cancer patients (reduction in tumor cell content through passive purging) . Bone Marrow Transplant . 1998;22:153–159
  18. Piacibello W , Sanavio F , Garetto L , et al.   Extensive amplification and self-renewal of human primitive hemopoietic stem cells from cord blood . Blood . 1997;89:2644–2653
  19. Gammaitoni L , Bruno S , Sanavio F , et al.   Ex-vivo expansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution . Exp Hematol . 2003;31:261–270
  20. Salomon DS , Brandt R , Ciardiello F , Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies . Crit Rev Oncol Hematol . 1995;19:183–232
  21. Prenzel N , Fischer OM , Streit S , Hart S , Ullrich A . The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification . Endocr Relat Cancer . 2001;8:11–31
  22. Carter P , Presta L , Goran CM , et al.   Humanization of an anti-p185HER2 antibody for human cancer therapy . Proc Natl Acad Sci U S A . 1992;89:4285–4289
  23. Pegram MD , Finn RS , Arzoo K , Beryt M , Pietras RJ , Slamon DJ . The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells . Oncogene . 1997;15:537–547
  24. Tokuda Y , Ohnishi Y , Shimamura K , et al.   In vitro and in vivo anti-tumour effects of a humanized monoclonal antibody against c-erbB-2 product . Br J Cancer . 1996;73:1362–1365
  25. Baselga J , Norton L , Albanell J , Kim YM , Mendelsohn J . Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts . Cancer Res . 1998;58:2825–2831
  26. Baselga J . New technologies in epidermal growth factor receptor-targeted cancer therapy . Signal . 2000;1:12–21
  27. Ciardiello F , Caputo R , Bianco R , et al.   Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Gefitinib), an epidermal growth factor receptor-selective tyrosine kinase inhibitor . Clin Cancer Res . 2000;6:2053–2063
  28. Albanell J , Cordony-Servat J , Rojo F , et al.   Activated extracellular signal-regulated kinase (association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments) . Cancer Res . 2001;61:6500–6510
  29. Albanell J , Rojo F , Averbuch S , et al.   Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients (histopathologic and molecular consequences of receptor inhibition) . J Clin Oncol . 2002;20:110–124
  30. Leone F , Perissinotto E , Viale A , et al.   Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction . Bone Marrow Transplant . 2001;27:517–523
  31. Wels W , Beerli R , Hellmann P , et al.   EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins . Int J Cancer . 1995;60:137–144
  32. Sliwkowski MX , Lofgren JA , Lewis GD , Hotaling TE , Fendly BM , Fox JA . Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) . Semin Oncol . 1999;26:60–70

PII: S1083-8791(05)00425-8

doi: 10.1016/j.bbmt.2005.06.003

Biology of Blood and Marrow Transplantation
Volume 12, Issue 1 , Pages 68-74 , January 2006

Article Tools

* Image Usage & Resolution